IRONWOOD PHARMACEUTICALS INC — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Ironwood raised full-year 2026 U.S. LINZESS net sales guidance to $1.15–$1.20 billion (from $1.125–$1.175B), driven by 4% prescription demand growth and significantly improved net pricing. Q2 2026 LINZESS U.S. net sales reached $282.3M (+14% YoY); collaboration revenue to Ironwood was $110.0M (+28% YoY). The company also repaid $200M in convertible notes in June 2026 using cash on hand and raised total 2026 revenue guidance to $460–$485M and adjusted EBITDA to >$310M.
Why this rating
Strong LINZESS growth and debt reduction are material for a $102.7M market-cap company. Guidance raise and 44% YoY revenue growth signal momentum, but base revenue ~$460–485M is modest relative to small size. Apraglutide remains early-stage.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.